Cardiac Gene Therapy When, Where and Why?

Dr. Alexander Lyon

Senior Lecturer and Consultant Cardiologist

Imperial College and Royal Brompton Hospital
National Heart and Lung Institute,
Imperial College, London

Imperial College London

MRC Medical Research Council

British Heart Foundation

Fondation Leducq

a.lyon@ic.ac.uk

OVERVIEW

- What is Cardiac Gene Therapy
- Clinical Gene Therapy
- The Past
- Cardiac Gene Therapy
  - Strategy
  - Clinical considerations
  - Gene Therapy Vectors
- The Present
- Candidate genes therapies for CCF
    - SERCA2a gene therapy
    - Development from bench to bedside
    - Arrhythmia Safety Studies
    - Clinical Trials
- The Future

Gene Therapy in Cardiac Failure



SERCA2a protein





Cardiac Gene Therapy

- Myocardial Ischaemia ★
  - Angioneogenesis
- Myocardial Dysfunction / Heart failure ★
  - Abnormal Ca^{2+} Cycling
  - Inflammation, cell survival, ECM remodelling

- Monogenic Cardiac Diseases
  - Ion Channelopathies
    - LQTS, SQTS, Brugada, CPVT
  - Familial DCM/HCM/ARVC
- Pulmonary Hypertension
- Atherosclerosis
- Tachyarrhythmias
- Biological pacemakers
- Cardiac Allograft Rejection

Clinical Gene Therapy

- Sceptism in Medical Community
- 20 years of ‘promises’
- Tragedies in 1990s
- Inadequate SAE reporting (37/940!)
- Conflicts of Interest
- Lack of Overt Progress during 1990s
  - Cardiac angioneogenesis trials – VEGF, FGF-4
  - NB adenoviral vector, transgene selection

Cardiac Gene Therapy
The Past

- AGENT trial programme
  - Angioneogenesis for myocardial ischaemia

  Vector Adenovirus
  Gene FGF-4
  Delivery IC infusion

  - AGENT 2 – Phase 2 – 52 pts 2:1 tx vs placebo
    - Non-significant trend to ↓ ischaemia
    - 13/35 pts SAEs – transient ↓ plts, ↑LFTS
  - AGENT 3 – Phase 3 trial – design 450 pts
    - Recruitment stopped after interim analysis 300 pts
    - No benefit

Cardiac Gene Therapy
The Past

- REVASC trial
  - Angioneogenesis for myocardial ischaemia

  Vector Adenovirus

  Gene VEGF121

  Delivery Surgical Intramyocardial injection
  - 77 pts stable angina – 35tx vs 32 placebo
  - Improved symptom scores and time to ST↓
  - No difference on myocardial perfusion scans
  - 1 death (post operative)
  - No vector related SAEs

Cardiac Gene Therapy
The Present

Clinical Gene Therapy
The Present

- New Regulation
  - FDA, EMEA
  - Cell and Gene Therapy Specific National Ethics Committees
- New Vectors
- New Clinical Gene Therapy Successes from 2006-present
  - Metastatic Melanoma
  - Haemophilia
  - Metastatic Breast Carcinoma
  - Leber's Congenital Amaurosis

Clinical Gene Therapy 2012



1793 patients worldwide
394 pts in Europe (~25%)

Clinical Gene Therapy 2012



Clinical Cardiac Gene Therapy Practical Issues

1. Delivery
2. Therapeutic Efficacy
3. Safety

No different to any other clinical treatment

Clinical Cardiac Gene Therapy Practical Issues

1. Delivery
   - Restrict gene expression to target tissue
     - myocardium
   - Effective gene transfer into cells

     ~ 10^{10}-10^{11} cardiomyocytes in human left ventricle
   - Effective gene expression
     - Timescale
       - » Transient
       - » Prolonged
       - » Lifelong
     - High levels for therapeutic efficacy

Answer Viral Vectors

Clinical Cardiac Gene Therapy Practical Issues

2. Therapeutic Efficacy

- Gene selection
- Effective protein production/suppression
- Biological effect
  - Does significant biological effect translate to significant clinical effect?
  - Can this be measured clinically?
- Clinical Outcomes
  - Functional endpoints
    - LVEF
    - LV Remodelling
    - Arrhythmias
    - Neurohormonal markers - BNP
    - QOL/symptoms/exercise tolerance
  - Morbidity and Mortality

Clinical Cardiac Gene Therapy Practical Issues

3. Safety

- Who?
  - Patient
  - Close contacts
    - Family
    - Sexual Partners
  - Future Children of Patient
  - Hospital Staff
  - Society
- Why?
  - Cardiac
    - Arrhythmias
    - Myocarditis
    - Increased impairment
  - Systemic
    - Off target effects
    - Inflammatory response syndromes
  - Malignancy
  - Vertical transmission

Viruses

Concerns re Unexpected Problems!

Viral Vectors in Registered Clinical Gene Therapy Trials




Viral DNA
New Gene
Viral DNA
Modified DNA injected into vector
Vector binds to cell membrane
Vector (adenovirus)
New gene
Vector injects new gene into nucleus
Vector is packaged in vesicle
Vesicle breaks down releasing vector
Cell makes protein using new gene
Gene therapy using an adenovirus vector

Viral Vectors for Cardiac Gene Therapy Advantages

- High levels of therapeutic gene expression
- Improve tissue targeting with natural tropism
- Produced in high quantities
- Candidates for Myocardial Gene Therapy:
  - Adenoviruses (Ad.)
  - Retroviruses + Lentiviruses (R+L)
  - Adeno-Associated Viruses (AAV)
- All clinical (and research) vectors are recombinant and non-replicating

Viral Vectors for Cardiac Gene Therapy Disadvantages

- Provoke immune response (esp. Ad.)
  - Reduces efficacy/duration of gene expression
  - Promotes immune response against host tissue
    - Myocarditis
    - Arrhythmias
  - Neutralising antibodies (all including AAV)
- Lack complete tissue specificity (Ad, R+L)
- Recombination with natural pathogenic viruses
- Cancer Risk
  - DNA integration can promote ‘insertional mutagenesis’ (R+L)
  - SCID children with Retrovirus Gene Therapy ↑Lymphomas
- Smaller viruses limit size of packaged gene (AAV)
- Expensive to produce in GLP/GMP facilities

Cardiac Gene Therapy
The Present
Adeno-Associated Viral Vectors



- Non-pathogenic
- Minimum immunogenicity
- Episomal
- Safety in Humans
  - haemophilia gene therapy trials
- Longterm gene expression in primate muscle studies
- Cardiotropic
  - AAV1
  - AAV6
  - AAV9
- Small
- Safe with immunosuppression in pigs
- NB FIX trial – upper dose ceiling

Which Protein/Gene?

MYOCARDIAL INJURY

e.g. Infarction, myocarditis, chemotherapy, mutation

Cardiomyocyte Loss



Myocardial Gene Therapy
Candidate Genes for Heart Failure

- Cardiomyocyte Ca^{2+} Cycling
  - SERCA2a ★
  - S100A1 ★
  - PLB (dn or as)
  - I-1c ★
- β Adrenoceptor Signalling Pathways
  - βARKct ★
  - Uptake 1
- Anti-inflammatory
  - Soluble TNFα Receptor Fragments
  - ROS Scavengers
    - Haemoxygenase 1
    - Superoxide Dismutase
- Antiapoptotic
  - Cyclin A

Cardiomyocyte Calcium Physiology
Excitation-Contraction Coupling





Image from Bers D. Nature 2002 <u>415</u>:198-205

SERCA2a in Heart Failure

- SERCA2a activity is reduced in Cardiomyocytes from failing hearts – human + animal models
- This causes:
  - Delayed removal of Ca^{2+} in diastole
  - Reduced velocity of diastolic relaxation, leading to increased diastolic chamber stiffness
  - Reduced SR Ca^{2+} stores for systolic release → Reduced inotropism
  - Increased frequency of afterdepolarisations
  - Contributes to action potential prolongation

} VT/VF

SERCA2a Gene Therapy and Heart Failure

- SERCA2a improves cardiac function
  - Ca^{2+} cycling + SR Ca^{2+} stores
  - Contractility
  - Relaxation
  - Energetics (NB vs dobutamine, milrinone etc)
- Isolated CM – failing human, rat, rabbit
- Animal HF models
    - Rat – Aortic Banding, Acute Post MI, Chronic Post MI HF
    - Mouse – Aortic Banding
    - Pig – Acute and Chronic MR
    - Sheep – Tachypacing HF

In Vitro Adenoviral transfection of myocytes from failing human ventricle



del Monte et al Circulation 1999

Effect of SERCA2a Gene Transfer on Survival in Rats with Pressure-Overload Hypertrophy in Transition to Heart Failure



del Monte et al Circulation 1999

Pig Chronic MR HF Model

AAV1.SERCA2a at 2months post MR

Assessment at Baseline, 2m (PREGENE) and 4m (POSTGENE







CUPID – Phase 2 Clinical Trial

Heart Failure

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID)

A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca^{2+}-ATPase in Patients With Advanced Heart Failure

Mariell Jessup, MD; Barry Greenberg, MD; Donna Mancini, MD; Thomas Cappola, MD; Daniel F. Pauly, MD, PhD; Brian Jaski, MD; Alex Yaroshinsky, PhD; Krisztina M. Zsebo, PhD; Howard Dittrich, MD; Roger J. Hajjar, MD; on behalf of the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators

Circulation 2011, 124:304-313: originally published online June 27, 2011
doi: 10.1161/CIRCULATIONAHA.111.022889

CUPID Trial Population
Severe Chronic Heart Failure: NYHA III/IV

- Stable advanced HF, LVEF <35%, MVO_2< 20 ml/kg/min
- Optimal medical and device therapy
- ICD

- Events in pre-screened patients (n=102)
  - Worsening Heart Failure n=11 (11%)
    - Transplant n=9 (9%)
    - Implanted LVAD n=2 (2%)
  - Other CV hospitalization=7 (7%)
  - All-Cause Death n=4 (4%)
- Total n=22 (22%) in 14 months

CUPID Trial
Patient enrollment



Clinical AAV SERCA2a Gene Therapy



CUPID Trial
Safety Results

- Well tolerated
- No adverse events secondary to infusion
- 4 transient positive ELISPOT tests
  - 2 concomitant disease
  - 2 asymptomatic
  - No associated troponin/CK /LFT rise
- No increase in arrhythmia on ICD interrogation

CUPID Phase 2 SERCA2a Gene Therapy Trial
Time to Multiple Clinical Events: 39 patients



CUPID Trial
Major Endpoints at 18 months
Death or Cardiac Transplantation

	DEATH	DEATH OR CARDIAC TRANSPLANT
PLACEBO	4/14	7/14 (50%)
LOW DOSE MYDICAR	3/8	4/8 (50%)
MID DOSE MYDICAR	0/8	2/8 (25%)
HIGH DOSE MYDICAR	0/9	1/9 (11%)

Serum Biomarker: NT-ProBNP



Exercise Test: 6 Minute Walk Test



FDA approval for a Phase 3 trial CUPID2 Trial granted April 2012

- International Multicentre Phase 3 trial
- Randomised, double blind, placebo controlled
- 200 pts with NYHA III-IV chronic systolic HF due to ischemic or dilated cardiomyopathy (LVEF <35%)
- Optimal medical and device HF therapy
- Randomised 1:1 to ‘high dose’ AAV1.SERCA2a gene therapy vs placebo ($1x10^{13}$ drp)
- AAV ab negative

FDA approval for a Phase 2/3 trial CUPID2 Trial

- Primary endpoint: Time-to-recurrent HF-related hospitalisation in the presence of terminal events (all cause death, heart Tx, LVAD)
- Secondary endpoints
  - time to terminal event (all cause death, heart Tx, LVAD), remodelling, biomarker, symptoms, QOL, safety
- 50 recruitment centres across US and Europe
- Aim to start Q4 2012
- Royal Brompton Hospital named UK recruitment centre
- UK National Coordinating Investigator

SERCA2a Gene Therapy for Heart Failure
Unexpected Surprises

Could SERCA2a gene therapy in the failing ventricle be proarrhythmic? Cellular and Subcellular Hypotheses

1. Cardiomyocyte Ca^{2+} cycling and arrhythmias
   - SR calcium leak arrhythmogenic
     - Ca^{2+} sparks → Ca^{2+} waves → DADs
     - DADs → Ventricular ectopics (trigger) + (?) Sustained VT
   - SR calcium overload → ↑ leak
   - ?↑SERCA2a →↑SR [Ca^{2+}] → ↑SR Ca^{2+} leak→↑ DADs

2. These arrhythmic mechanisms are potentially amplified with β1AR + β2AR activation
   - PKA – PLB, RyR2, I-1
   - CaMKII – RyR2, PLB

Could SERCA2a gene therapy in the failing ventricle be proarrhythmic? Multicellular, Tissue and Intact Organ Levels

3. APD heterogeneity – arrhythmogenic – local reentry
   - Reduced Ca^{2+} transients contributes to APD prolongation
   - SERCA2a expression shortens APD
   - Patchy SERCA2a transfection - ? ↑heterogeneity of APD

4. T wave and APD alternans arrhythmogenic
   - Secondary to discordant calcium alternans
   - Gradients maximal where SERCA2a expression lowest

HF Model



Serum BNP



Myocardial SERCA2a





ESPVR



EDPVR



Lyon AR et al PNAS 2009 106 (16) 6854-59.

SERCA2a Gene Therapy Arrhythmia Studies

MI

In vivo
24 hour ECG recording + ISO challenge (PREGENE)

In vivo
Intramyocardial Ad.SERCA2a.GFP Gene Injection x3

In vivo
24 hour ECG recording + ISO challenge (POSTGENE)

Ex vivo
Langendorff: PES Challenge Western Blotting PV Loops



Wk1 **15** **16** **16+6/17** **17+1**



SERCA2a Gene Therapy is a Positively Inotropic and Lusitropic in the Chronic Post MI HF Model











* p<0.05 **p<0.01 ***p<0.001 vs HF

Lyon AR et al *Circ Arrhythm Electrophysiol* 2011;4;362-372

In Vivo Arrhythmia Assessment
Spontaneous Ventricular Arrhythmias





CVAs = Couplets, Triplets,VT and VF

n=8 per study arm *p<0.05, **p<0.01 and ***p<0.001 vs HF and HF + GFP

Lyon AR et al Circulation Arrhythmia Electrophysiology 2011 4:362-372

In Vivo Arrhythmia Assessment
ISO-Induced Ventricular Tachycardia

*p<0.05 and **p<0.01 vs HF



Lyon AR et al Circulation Arrhythmia Electrophysiology 2011 4:362-372

What are the mechanisms underlying the antiarrhythmic effect of SERCA2a gene therapy?

Mechanisms of Arrhythmogenesis in Chronic Heart Failure

- Subcellular
- Cellular
- Intact heart

Cardiac Gene Transduction by AAV9 Vectors



Pacak et al Circ Res 2006 99 3-9



Suckau et al Circ 2009 119 1241-52



T . Vandendriessche et al. J. Thromb. Haem. 5 16-24

Intravenous SERCA2a Gene Therapy



AAV9.SERCA2a gene therapy normalises SR Ca^{2+} content





SR Ca^{2+} Load



Peak Caffeine transient (F/F0)



AMC n=8, HF n=12, HF+SERCA n=9 * p<0.05

Sparkology

Spontaneous SR Ca^{2+} spark frequency unchanged in failing myocytes after AAV9.SERCA2a gene transfer





Number of sparks/cells/hearts:
AMC=247/19/7
HF=853/30/11
HF+SERCA=445/10/5
***p<0.05, **p<0.01**



Lyon AR et al *Circ Arrhythm Electrophysiol* 2011;4;362-372

SERCA2a Gene Therapy Reduces Spark-mediated SR Calcium Leak









Number of sparks/ cells/hearts:
AMC=247/19/7
HF=853/30/11
HF+SERCA=445/10/5
***p<0.05, **p<0.01, ***p<0.001**

Lyon AR et al *Circ Arrhythm Electrophysiol* 2011;4;362-372

SERCA2a Overexpression Suppresses Ca^{2+} and APD Alternans in the Heart Failure Guinea Pig HF Model +/- AAV9.SERCA2a



Courtesy of Cutler M, Hajjar RJ, Rosenbaum DS (in press)

SERCA2a Gene Therapy

- Positive Inotrope
- Positive Lusitrope
- Antiarrhythmic
- Improves Myocardial Energetics

- Benefits in small and large animal HF models
- Benefits and safe in a small Phase 2 trial

- Await outcome of the 2 clinical trials
  - Clinical endpoints
  - Biological success

Cardiac Gene Therapy
The Future

Cardiac Gene Therapy
The Future
Which Gene?

Cardiac Gene Therapy
The Future
Which Gene?

- siRNA

Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy

Suckau et al Circulation 2009 119 1241-52

- MicroRNA

Silencing of microRNAs *in vivo* with 'antagomirs'

Jan Krützfeldt[1], Nikolaus Rajewsky[2], Ravi Braich[3], Kallanthottathil G. Rajeev[3], Thomas Tuschl[2], Muthiah Manoharan[3] & Markus Stoffel[1]

Krutzfeldt et al Nature 2005 438 685-689

Cardiac Gene Therapy
The Future

Novel Gene Expression Control Systems

- Tissue specific
  - Promoters
  - Activation
- Drug Inducible
  - ‘Physician control’
  - Organ targeting
- Negative feedback eg BNP
  - ‘Disease control’

Cardiac Gene Therapy
The Future

- Novel Delivery Techniques
  - Physical Targeting
  - Microbubbles





Muller et al Gene Therapy 2008 15 1558-65

Cardiac Gene Therapy
The Future

Novel Vectors

AAV9



Cardiac Gene Therapy
The Future

Novel vectors

- Bioengineered AAVs
  - Reduced immunogenicity, neutralizing Abs
  - Improve purification
  - Increase cardiac specificity

- Subcutaneous ‘biopumps’

Chimeric rAAV



Courtesy of Dr. Jude Samulski

Combined Gene and Cell Therapy Strategies

- Improve Quality of Stem Cell Therapies
  - Delivery
  - Survival
  - Efficacy
  - Cardiomyogenesis
- Improve function of failing CM
  - Paracrine effect
- Inducible Pluripotent Stem Cells (IPCs)
- Biological Pacemakers (I_f)

Gene Therapy for Heart Failure Summary

- Need for New Therapeutic Strategies for Heart Failure
- Cardiac Gene Therapy
  - Developed on a base of >20 years myocardial biology
  - Regulation stringent
  - New Viral Vectors - AAV
    - safe
    - higher transfection efficiency
    - long lasting expression
- SERCA2a Gene Therapy
  - Positive Inotrope
  - Positive Lusitrope
  - Antiarrhythmic
  - Improves Myocardial Energetics
- Phase 2 SERCA2a trial in US
  - Safe
  - Efficacy
- UK Trial 2011
- FDA approved Phase 3 Trial
- Judge on Clinical Outcomes